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RESPONSE TO EXAMINER’S COMMENTS:  
The second protocol study objective of comparing the incidence/prevalence  of dyslipidaemia 
in different age groups was not fully met and the reason that this wasn’t done is not 
elaborated on in the paper. The age groups we re changed to < 10 years and > 10 years. I 
feel that it would be beneficial to keep the original age groups  and compare children 0-5 
years, 5-10 years and 15-19 years as these age groups are likely to have been exposed to 
different ART regimens and to have different disease profiles. If the numbers were too small, 
then the age breakdown of the children should be more clearly explained as the range is too 
broad. 
I couldn’t meet this objective because of the large number of missing variables  making it 
impossible to do the analysis for 4 groups. For example, at baseline (ART initiation) only 7% 
(146/2145) patients had any lipids measured, with no lipid measurements in the 17 patients 
15-19 years old (see results paragraph 2). For that reason, I limited the analysis to 2 age 
groups: children (<10 years) and adolescents (≥ 10 years).  The age range is explained in 
methods, paragraph 6 and addressed in the study limitations  (see discussion, paragraph 6). 
All edits in blue for easy reference.  
 
ABSTRACT  
The abstract is concise. It is difficult to understand if the paper hasn’t been read first as it is 
not explained what is meant by 12 and 24 months. This needs to be clarified to improve 
understanding: “12 and 24 months after starting LPV/r.” 
Agreed. I have made the suggested edits on the attached abstract . 
It is stated that the median age at ART-start was 1.6 years…. 
Agreed. I have added this important info rmation in the results section of the paper, 
paragraph 1. 
It states: “At 24 months on LPV/r, ART duration greater than 60 months was an additional 
protective factor.” Either additional should be removed or high VL added.  
I have added high VL. 
It would be relevant to describe how many children out of the potential population actually 
were included in the study and how many children had no data. 
I have included this data in the results section. 
 
INTRODUCTION 
I feel that it would be relevant to discuss the effects of NRTI’s such as D4T, AZT and DDI on 
lipid profiles as many children were likely on these NRTIs. 
The patients were on varying NRTI backbones. In the initial analyses I stratified based on 
the NRTI backbones, those that are associated with dyslipidaemia (stavudine, zidovudine, 
didanosine) and those that are not associated with dyslipidaemia (lamivudine, ab acavir and 
tenofovir); I found no association. Low numbers could have been a limiting factor. In the end 
I decided to focus on LPV/r and LPV/r with additional ritonavir as boosting for rifampicin -
based TB treatment. The time periods (before or after 2010) are essentially a proxy for the 
different NRTI backbones as described above. However, since I found no statistical 
difference using the NRTI backbones themselves, a time -based analyses is not warranted. 
The suggested corrections were made in paragraph 4 of the introduction, paragraph 1 of 
methods, paragraph 10 of results and paragraph 5 of the discussion.  
 
The normal effect of age on lipid profiles should also be discussed as these children were a 
wide age range (Birth-19 years). 
This study focused on the effect on lopinavir/retinovir (LPV/r) on dyslipidaemia. In the 
introduction I mention that there are physiological changes in lipid profiles in children . I have 
expanded on what these changes are (paragraph 4) . 
METHODS 
The age range of the study is not clearly stated except in the first table. 
Age range added in the methods section, paragraph 3. 
How many children were potentially on d4T, AZT or DDI for the entire 24 months period? 
These NRTIs have all potentially been linked with dyslipidaemia and it would therefore be 
important to document the NRTI backbone if possible or to compare children on treatment 
before 2010 to those on treatment after 2010. 
I am not able to report on the proportion of children on d4T, AZT or DDI for the  study period 
as I no longer have access to the data. However, in the analysis based on NRTI backbone I 
found no association with dyslipidaemia at all 4 time points. 
 
RESULTS 
It needs to be clearly explained both in Table 1 and in the first paragraph, when  the data was 
captured. 
Suggested edits made in Table 1 and results section of the paper, paragraph 1 . 
‘Demographic and clinical characteristics of 2145 children started on a lopinavir/ritonavir 
containing regimen at ART start (either NNRTI or PI based)’. I am not sure if the table 
reflects data at LPV/r start. How many children was 1 st ART start=LPV/r start? There is no 
explanation for # in the table 
Suggested edits and clarification made in Table 1 and results section of the paper, 
paragraph 1. 
It is reassuring that children who did and didn’t have lipids measured were similar. It would 
be important to make sure that they were also on similar NRTI backbones.  
I am not able to report on this as I no longer have access to the data .  
It is confusing that paragraph 1 states that anthropometric z-scores were normal at ART start 
whereas paragraph 3 says that in children who had lipids taken, 70% of the children were 
underweight and stunted at ART and LPV/r start! This needs to be explained as the 
sensitivity analysis suggests that there is no difference in anthropometry between those who 
had lipids measured and those who didn’t. 
Overall the anthropometric z-scores were normal at ART start. However, the age group <5 
was the only group that was stunted and underweight (see Table 1). I postulate that this was 
due to the young children even though the sensitivity analysis doesn’t show any significant 
age difference between the children with measured lipids and those without at these 2 time 
points. This is highlighted at the end of paragraph 1, results section. 
The degrees of underweight, stunting and BMI are also slightly different in the ART and 
LPV/r start groups not the same as suggested in the text . 
The table refers to normal anthropometry, with the abnormal (un derweight, stunted and 
wasted) inferred. The paper speaks to the abnormal anthropometry.  I have edited the text to 
correlate with the table. 
Table 2 is missing the m after 24 in the heading. 
Corrected. 
Dyslipidaemia is clearly defined but doesn’t explain figure 1 and supplementary figure 2. If 
dyslipidaemia is defined as hypercholesterolaemia and/or hypertriglyceridaemia how is it 
possible for the percentage of patients with dyslipidaemia to be less than  the number with 
hypertriglyceridaemia? 
I have verified all the numbers, and it’s correct. The reason the hypertriglyceridaemia is 
higher than the dyslipidaemia is because of different denominators. For example (refer Table 
2) at ART start, there are 133 measured triglycerides vs 146 measured cholesterols; thus the 
dyslipidaemia is calculated with a higher denominator. Similarly, for the small cohort of 
children with measured lipids at all 3 time points: there were 16 measured triglycerides vs 19 
measured cholesterols. 
If there is uncertainty about the definition of dyslipidaemia, what definition was used to do 
the multivariate analysis? Was separate analysis done for triglycerides and cholesterol or 
were they combined into one category ‘dyslipidaemia’ consisting of either AND/OR one of 
them? This needs to be clearly defined. 
The definition of dyslipidaemia given in the methods section, paragraph 5 was used in all 
multivariate analyses. 
It would be interesting if the group with lipids measured at all four tim e points could be better 
described mentioning such things as age, viral suppression and NRTI backbone.  
The cohort of children with measures lipids at all 3 time points: the age is mentioned in 
paragraph 5. I am unable to report on the viral suppression and NRTI background as I no 
longer have access to the data. 
Table 3 is a little confusing. If ART start was = LPV/r start were children included in both 
groups? How many children had ART start = LPV/r start?  
ART start is only the same as LPV/r start in the cohort of children who had all measured 
lipids. However, outside of this cohort for those children who had ART start = LPV/r start 
they were included in both groups. The number of children who had ART start  = LPV/r start 
is shown in Table 2.  
 Why is BMIZ score for children > 10 years at ART start empty?   
There were very few measured lipids in this group of children to allow for proper analysis 
(only 6 measured lipids in the normal BMIZ category) 
DISCUSSION 
The fact that a suppressed viral load was associated with increased risk of dyslipidaemia 
seems to be contradictory to the fact that ART duration greater than 60 months was a 
protective factor. This could be better discussed – was it due to different ART exposure? 
A possible explanation for this finding is offered in paragraph 4 of the discussion.  
The long term effects of increased total cholesterol with an improved tr iglyceride profile are 
unknown and the fact that only total cholesterol was measured and n ot LDL or other factors 
such as inflammatory markers that are better linked to cardiovascular outcomes was not 
discussed. The improvement of triglyceride s on cardiovascular outcomes also wasn’t 
discussed. 
Agreed. This is briefly mentioned in paragraph 4 of the discussion. I have expanded on this 
in paragraph 5. 
 
 
 
